alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
H. R. 3364

One Hundred Fourth Congress

of the

United States of America

AT THE SECOND SESSION

Begun and held at the City of Washington on Wednesday,

the third day of January, one thousand nine hundred and ninety-six

An Act

To designate the Federal building and United States courthouse located at 235

North Washington Avenue in Scranton, Pennsylvania, as the ‘‘William J. Nealon

Federal Building and United States Courthouse’’.

SECTION 1. DESIGNATION.

The Federal building and United States courthouse located

at 235 North Washington Avenue in Scranton, Pennsylvania, shall

be known and designated as the ‘‘William J. Nealon Federal Building and United States Courthouse’’.

SEC. 2. REFERENCES.

Any reference in a law, map, regulation, document, paper,

or other record of the United States to the Federal building and

United States courthouse referred to in section 1 shall be deemed

to be a reference to the ‘‘William J. Nealon Federal Building and

United States Courthouse’’.

Speaker of the House of Representatives.

Vice President of the United States and

President of the Senate.
T hi s di s pos i t i on i s notappr opr i a t e f orpubl i c a t i on and i s notpr e c e de nt * e xc e pta s pr ovi de d byN i nth C i r c ui tR ul e 36- 3.

T he pa ne l una ni m ous l yc onc l ude s thi s c a s e i s s ui t abl e f orde c i s i on ** w ith o u t o r a l a r g u m e n t. See F ed. R . A pp . P . 34 (a )( 2). NOT F OR P UB L I CAT I ON UN I TE D STATE S C OU RT OF APPE ALS FOR T HE NI NTH CI RC UI T I n r e : S T E P H E N L A W, D ebt or, S T E P H E N L A W, A p p e lla n t, v. A L F R E D H . S IE G E L , C hapt er7 T rust ee , A pp el l ee . N o. 09- 60023 B A P N o . C C - 0 8 - 1 2 4 0 - Mk H Mo ME MOR AN DU M *

A p p e a l f r o m th e N in th C ir c u it B ankrup t cyA pp el l at e P anel M a rke l l , H ol l ow e l l , a nd M ont a l i , B a nkrupt c yJ udge s , P r e s i di ng

S ubm i tt e d M a y24, 2011 ** B efo re: P R E G E R S O N , T H O M A S , an d P A E Z , C i rcu i tJu d g es. 

# FI LED JU N 06 2011 M OLLY C. DW Y ER, CLERK U . S. C O U R T OF APPE ALS09- 60023 2 S t ephen L aw appeal s pro se fr om the B ankrup t cyA pp el l at e P anel ’ s ( “ B A P ”) or de ra f f i rm i ng the ba nkrupt c yc ourt ’ s or de rdi s m i s s i ng hi s a dve r s a ryc om pl a i nt a ga i ns tthe trus t e e i n hi s C hapt e r7 ba nkrupt c ypr oc e e di ngs . W e ha ve j ur i s di c t i on un der 28 U . S . C . § 1 58 (d). W e r evi ew de no vo a di sm i ss al for f ai l ure t o st at e a c la im u n d e rF e d . R . C iv . P . 1 2 ( b ) ( 6 ) . N . S lo p e B o ro u g h v. R o gsta d

(In re R ogs tad) , 1 2 6 F. 3 d 1 2 2 4 , 1 2 2 8 ( 9 th Ci r . 1 9 9 7 ) . W e a f f i rm. C ontr a ryt o L a w ’ s c ont e nt i on, the ba nkrupt c yc ourtha d j ur i s di c t i on ove rthe r e m ove d s t a t e - l aw c l a i m s a ga i ns tthe trus t e e be c aus e the yc onc e rne d the a d m in is tr a tio n o f

th e b a n k ru p tc ye s ta te . See M a itla n d v . Mitc h e ll (

I n r e H a rr is P i n e Mi l l

s) , 44 F . 3d 14 31 , 14 38 (9th C i r. 19 95 ) ( pl ai nt i ff s’ po stpet i t i on st at e- l aw c l a i m s a ga i ns tthe ba nkrupt c ytrus t e e “ f orc onduc ti ne xtr i c abl yi nt e rtw i ne d w i th the trust ee ’ s s al e of property bel on gi ng t o the bank rupt cyes t at e i nv ol ved a core p r o c e e d in g s u b

je c t to f e d e r a l ju r is d ic tio n ” ) . T h e B A P p r o p e r lyd e te rm in e d th a t L a w ’s c o m p la in t f a ile d to s ta te ac la im a g a in s t th e tru s te e b e c au s e th e a lle g a tio n s a g a in s t th e tru s te e c o n c e rn e d h is c o u rtau th o r iz e d m a n a g e m e n t o f th e b a n k ru p tc ye s ta te , f o rw h ic h h e e n

jo y e d im m u n ity . See B e n n e t t

v . Wi l l i a ms , 89 2 F . 2d 82 2, 82 3 (9th C i r. 19 89 ) ( “ B ankrup t cytrust ee s a r e e n title d to b r o a d im m u n ityf r o m s u it w h e n a c tin g w ith in th e s c o p e o f th e ir au th o r itya n d p u r s u a n t to c o u rt o r d e r .” ) .09- 60023 3 L a w ’s r e m a in in g c o n te n tio n s a r e u n p e r s u a s iv e . AF F I RME D.
#### § 424.200 Scope.

This subpart specifies the requirements for Medicare Diabetes Prevention Program suppliers and beneficiary engagement incentives under the Medicare Diabetes Prevention Program expanded model.
#### STATE of Louisiana ex rel. Peter LEWIS v. Hayden J. DEES, Warden, Dixon Correctional Institution.

No. 62914.

Supreme Court of Louisiana.

Oct. 20, 1978.

In re: Peter Lewis, applying for writ of certiorari. Parish of Orleans.

Writ denied.
§ 408.50 When premiums are considered paid. ( a ) *Actual deduction.* A premium is considered paid if it is actually deducted from a monthly benefit check. Therefore— ( 1 ) The premium is “paid” even if SSA later finds that the benefit was paid in error; but
( 2 ) A finding that a monthly benefit was erroneously withheld does not constitute payment of the premium for that month. Since there was no payment, there was no deduction. The enrollee is billed and continuance of coverage depends on payment of premiums before the end of the grace period or extended grace period.
( b ) *Payment within the grace period.* Overdue premiums are considered paid within the grace period in the following situations: ( 1 ) *Benefits are resumed during the grace period.* ( i ) Monthly cash benefit payments are payable for the last month of the initial grace period or for earlier months on the basis of a notice filed by the enrollee before the initial grace period ends; and
( ii ) Those payments are sufficient to permit deduction of all overdue premiums.
( 2 ) *Annual earnings report or other report submitted during the grace period shows a benefit is due.* ( i ) Before the end of the grace period, the enrollee submits a report clearly showing that monthly cash benefits, previously withheld, are payable; and
( ii ) Those benefits are sufficient to permit deduction of the full amount of the overdue premiums.
( 3 ) *Premium arrears are paid by direct remittance.* The enrollee makes a direct remittance payment of all overdue premiums before the end of the grace period.
[52 FR 48115, Dec. 18, 1987; 53 FR 4159, Feb. 12, 1988; 56 FR 48112, Sept. 24, 1991]
# C_2006154EN.01000902.xml

| 1.7.2006 | EN | Official Journal of the European Union | C 154/9 |
| --- | --- | --- | --- |

1.7.2006

EN

Official Journal of the European Union

C 154/9

---

Reference for a preliminary ruling from the Court of Appeal (Civil Division) (England and Wales) made on 14/04/2006 — The Queen on the application of British Telecommunications plc v Commissioners for HM Revenue and Customs

(Case C-185/06)

(2006/C 154/20)

Language of the case: English

Referring court

Court of Appeal (Civil Division) (England and Wales)

Parties to the main proceedings

Applicant: British Telecommunications plc

Applicant:

Defendant: Commissioners for HM Revenue and Customs

Defendant:

Questions referred

| 1. | Does the European law right to the repayment of improperly levied sums by tax authorities, referred to by the ECJ in paragraph 84 of the Judgment in Metallgesellschaft v. CIR (Joined Cases C-397/98 and C-410/98), apply equally to the repayment of sums paid voluntarily by a taxpayer to a tax authority in error (where the tax authority did not contribute to that error and had no reason to be aware of it), or is it a matter for domestic law? |
| --- | --- |

1.

Does the European law right to the repayment of improperly levied sums by tax authorities, referred to by the ECJ in paragraph 84 of the Judgment in Metallgesellschaft v. CIR (Joined Cases C-397/98 and C-410/98), apply equally to the repayment of sums paid voluntarily by a taxpayer to a tax authority in error (where the tax authority did not contribute to that error and had no reason to be aware of it), or is it a matter for domestic law?

| 2. | If European law does confer a right to the repayment of such sums in such circumstances, does it also give rise to a right to interest on the amounts repaid, or is it a matter for domestic law, as suggested by paragraph 86 of the Judgment of the ECJ in Metallgesellschaft? |
| --- | --- |

2.

If European law does confer a right to the repayment of such sums in such circumstances, does it also give rise to a right to interest on the amounts repaid, or is it a matter for domestic law, as suggested by paragraph 86 of the Judgment of the ECJ in Metallgesellschaft?

| 3. | If European law does confer a right to interest on the repayment of such sums in such circumstances is that a right to simple interest or to compound interest? |
| --- | --- |

3.

If European law does confer a right to interest on the repayment of such sums in such circumstances is that a right to simple interest or to compound interest?

---
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                         601,116
<SECURITIES>                                         0
<RECEIVABLES>                                  730,767
<ALLOWANCES>                                    50,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                             3,321,492
<PP&E>                                         814,560
<DEPRECIATION>                                 706,111
<TOTAL-ASSETS>                               7,889,196
<CURRENT-LIABILITIES>                        5,137,588
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  2,235,674
<COMMON>                                        72,119
<OTHER-SE>                                     262,563
<TOTAL-LIABILITY-AND-EQUITY>                 7,889,196
<SALES>                                      1,414,186
<TOTAL-REVENUES>                             1,414,186
<CGS>                                          973,140
<TOTAL-COSTS>                                1,499,471
<OTHER-EXPENSES>                               (3,575)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              50,658
<INCOME-PRETAX>                              (132,187)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (132,187)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (132,187)
<EPS-PRIMARY>                                    (.24)
<EPS-DILUTED>                                    (.24)
        

</TABLE>
##### 



Exhibit 32.1
 SECTION 1350 CERTIFICATION
  1.
    
    The Annual Report on Form 10-K of the Company for the annual period ended December 31,
2007 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and2.
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 /s/ Donita R. KovalDonita R. Koval
Chief Executive Officer

    Date: 03/17/2008  SECTION 1350 CERTIFICATION
  1.
    
    The Annual Report on Form 10-K of the Company for the annual period ended December 31,
2007 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and2.
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 /s/ Daniel L. WarfelDaniel L. Warfel
Chief Financial Officer

    Date: 03/17/2008  63
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CHIRON
CORPORATION'S CONSOLIDATED BALANCE SHEET DATED DECEMBER 31, 1995, AND
CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 1995, AND
NOTES THERETO AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               DEC-31-1995
<CASH>                                          74,318
<SECURITIES>                                   149,899<F1>
<RECEIVABLES>                                  285,779
<ALLOWANCES>                                    18,524
<INVENTORY>                                    165,941
<CURRENT-ASSETS>                               637,003
<PP&E>                                         658,579
<DEPRECIATION>                                 140,761
<TOTAL-ASSETS>                               1,490,198
<CURRENT-LIABILITIES>                          368,595
<BONDS>                                        420,188<F2>
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           417
<OTHER-SE>                                     671,995<F3>
<TOTAL-LIABILITY-AND-EQUITY>                 1,490,198
<SALES>                                        922,853
<TOTAL-REVENUES>                             1,100,582
<CGS>                                          415,798
<TOTAL-COSTS>                                  415,798
<OTHER-EXPENSES>                             1,167,212<F4>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              30,362<F5>
<INCOME-PRETAX>                              (490,774)
<INCOME-TAX>                                    21,689
<INCOME-CONTINUING>                          (512,463)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (512,463)
<EPS-PRIMARY>                                  (12.62)
<EPS-DILUTED>                                  (12.62)
<FN>
<F1>CONSISTS OF BOTH SHORT-TERM AND NONCURRENT INVESTMENTS IN MARKETABLE DEBT
SECURITIES.
<F2>CONSISTS OF CONVERTIBLE SUBORDINATED DEBENTURES, CAPITAL LEASE OBLIGATIONS AND
NOTES PAYABLE.
<F3>CONSISTS OF ADDITIONAL PAID-IN CAPITAL, ACCUMULATED DEFICIT, CUMULATIVE FOREIGN
CURRENCY TRANSLATION ADJUSTMENT AND UNREALIZED GAIN FROM INVESTMENTS.
<F4>CONSISTS OF RESEARCH AND DEVELOPMENT; SELLING, GENERAL AND ADMINISTRATIVE;
WRITE-OFF OF IN-PROCESS TECHNOLOGIES; COSTS RELATED TO CIBA TRANSACTION;
RESTRUCTURING AND REORGANIZATION CHARGES AND OTHER OPERATING EXPENSES.
<F5>CONSISTS OF INTEREST EXPENSE AND RELATED COSTS ON CONVERTIBLE DEBENTURES AND
OTHER INTEREST EXPENSE.
</FN>
        

</TABLE>
Mar 13 14 03:55p Aviation Multinational 786-2332561 p.1



### March 13, 2014 REFERENCE NO.**FAA~2012-1058** Docket Operations, M-30; U.S. Department of Transportation (DOT}, 1200 

### New Jersey Avenue, 

### SE., Room 

### W12-140, West Building Ground Floor, Washington, DC 20590-0001**~··-·**



### ....**~.**

This letter is in support of the FAA requirements of drug testing for foreign personnel. There should be no difference requirements for foreign personnel than for US residents. . I:

The likelihood of the use of drugs in foreign countries is much higher than in the US. We should

## ~require dr.tiOesting outside the US .
... r· f**.~:..1'** ..... 

### i /**~__,..·#** 

# . t**iFba~Gu~1**

### '~--,~~-./~IY/l?.......-~1:**~r<J/** 

### .... <i.J-'**t~..,...-~V** //'. Javier**Rodrigue.v;~·** 

### I**~.** 

### .... :.:- ld: ....**'~·** J

### ~**.~**

. 

### ..--·

Tel: 954.382.3405 • Cell: 954.290.5616 • Fax: 954.382.3405 E-Mail: aviationm\lltinational@gmail.com • www.aviationmultinational.org 1086 N.W. 96th Avenue • Plantation, Floric:fa 33322 USA
#### STATE of Florida et al., Petitioners, v. Ernest DAVIS, Respondent.

No. 74-838.

District Court of Appeal of Florida, Fourth District.

July 26, 1974.

Certiorari dismissed.
EXHIBIT
(10)W


 


POLICY ON REIMBURSEMENT


OF INCENTIVE PAYMENTS


 


The
Board shall, in all appropriate circumstances and to the extent permitted by
governing law, require reimbursement of any improper annual incentive payment
or long-term incentive payment to an Executive. 
If the Board determines any Executive has received an improper
payment to the Executive due to such Executive’s Misconduct, the Executive must
return the improper payment to the extent it would not have been paid or
awarded had the misconduct not occurred.  Improper payments can include an incentive
payment, a stock grant paid or awarded, or gain from a stock grant.   All
Executives are required to agree to this policy in writing.


 


“Misconduct”
means any material violation of the Ecolab Code of Conduct or other fraudulent
or illegal activity for which the Executive is personally responsible, as
determined by the Board.


 


 “Executive” means executive officer for
purposes of the Securities Exchange Act of 1934, as amended.


 


Agreed to this       
day of

                          ,
20      .


 


	
   

  	
  Signature:

  	
   

  
	
   

  	
   

  
	
   

  	
  Print
  Name:
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3223 Introduced in House (IH)]

104th CONGRESS
  2d Session
                                H. R. 3223

   To amend title 18, United States Code, to provide mandatory life 
 imprisonment for persons convicted of a second serious violent felony 
                        or serious drug offense.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 29, 1996

Mr. Schiff (for himself, Mr. McCollum, Mr. Coble, Mr. Skeen, Mr. Frost, 
 Mrs. Myrick, and Mr. LaTourette) introduced the following bill; which 
             was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
   To amend title 18, United States Code, to provide mandatory life 
 imprisonment for persons convicted of a second serious violent felony 
                        or serious drug offense.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Two Strikes Act of 1996''.

SEC. 2. MANDATORY LIFE IMPRISONMENT FOR PERSONS CONVICTED OF SECOND OR 
              SUBSEQUENT SERIOUS VIOLENT FELONIES OR SERIOUS DRUG 
              OFFENSES.

    Paragraph (1) of section 3559(c) of title 18, United States Code, 
is amended by striking ``if--'' and all that follows through the end of 
such paragraph and inserting ``if the person has been convicted (and 
that conviction has become final) on a separate prior occasion, in a 
court of the United States or a State, of one or more serious violent 
felonies or one or more serious drug offenses.''.
                                 <all>
```
§ 425.500 Measures to assess the quality of care furnished by an ACO for performance years (or a performance period) beginning on or before January 1, 2020. ( a ) *General.* CMS establishes quality performance measures to assess the quality of care furnished by the ACO. If the ACO demonstrates to CMS that it has satisfied the quality performance requirements in this subpart, and the ACO meets all other applicable requirements, the ACO is eligible for shared savings.
( b ) *Selecting measures.* ( 1 ) CMS selects the measures designated to determine an ACO's success in promoting the aims of better care for individuals, better health for populations, and lower growth in expenditures.
( 2 ) CMS designates the measures for use in the calculation of the quality performance standard.
( 3 ) CMS seeks to improve the quality of care furnished by ACOs over time by specifying higher standards, new measures, or both.
( c ) ACOs must submit data on the measures determined under paragraph (b) of this section according to the method of submission established by CMS.
( d ) *Patient experience of care survey.* ( 1 ) For performance years (or a performance period) beginning in 2014 through 2019, ACOs must select a CMS-certified vendor to administer the survey and report the results accordingly.
( 2 ) For performance year 2020, CMS waives the CAHPS for ACOs reporting requirement and will assign all ACOs automatic credit for the CAHPS for ACOs survey measures.
( e ) *Audit and validation of data.* CMS retains the right to audit and validate quality data reported by an ACO. ( 1 ) In an audit, the ACO will provide beneficiary medical records data if requested by CMS.
( 2 ) If, at the conclusion of the audit process the overall audit match rate between the quality data reported and the medical records provided under paragraph (e)(1) of this section is less than 80 percent, absent unusual circumstances, CMS will adjust the ACO's overall quality score proportional to the ACO's audit performance.
( 3 ) If, at the conclusion of the audit process CMS determines there is an audit match rate of less than 90 percent, the ACO may be required to submit a CAP under § 425.216 for CMS approval.
( f ) Failure to report quality measure data accurately, completely, and timely (or to timely correct such data) may subject the ACO to termination or other sanctions, as described in §§ 425.216 and 425.218.
[76 FR 67973, Nov. 2, 2011, as amended at 81 FR 80559, Nov. 15, 2016; 82 FR 53370, Nov. 15, 2017; 85 FR 85040, Dec. 28, 2020] Editorial Note
Editorial Note: At 82 FR 53370, Nov. 15, 2017, § 425.500 was amended; however, a portion of the amendment could not be incorporated due to inaccurate amendatory instruction.
#### § 412.370 General provisions for hospitals located in Puerto Rico.

Except as provided in § 412.374, hospitals located in Puerto Rico are subject to the rules in this subpart governing the prospective payment system for inpatient hospital capital-related costs.
§ 425.708 Beneficiaries may decline claims data sharing. ( a ) Beneficiaries must receive notification about the Shared Savings Program and the opportunity to decline claims data sharing and instructions on how to inform CMS directly of their preference. ( 1 ) FFS beneficiaries are notified about the opportunity to decline claims data sharing through CMS materials such as the Medicare & You Handbook and through the notifications required under § 425.312.
( 2 ) The notifications provided under § 425.312 must state that the ACO may have requested beneficiary identifiable claims data about the beneficiary for purposes of its care coordination and quality improvement work, and inform the beneficiary how to decline having his or her claims information shared with the ACO in the form and manner specified by CMS.
( 3 ) Beneficiary requests to decline claims data sharing will remain in effect unless and until a beneficiary subsequently contacts CMS to amend that request to permit claims data sharing with ACOs.
( b ) The opportunity to decline having claims data shared with an ACO under paragraph (a) of this section does not apply to the information that CMS provides to ACOs under § 425.702(c).
( c ) In accordance with 42 U.S.C. 290dd-2 and the implementing regulations at 42 CFR part 2, CMS does not share beneficiary identifiable claims data relating to the diagnosis and treatment of alcohol and substance abuse without the explicit written consent of the beneficiary.
( d ) The provisions of this section relate only to the sharing of Medicare claims data between the Medicare program and the ACO under the Shared Savings Program and are in no way intended to impede existing or future data sharing under other authorities.
[76 FR 67973, Nov. 2, 2011, as amended at 80 FR 32840, June 9, 2015]